Global Non-invasive Brain Stimulation System Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Technology (Transcranial Magnetic Stimulation (TMS), Transcranial Electrical Stimulation (tES)), By Application (Major Depressive Disorder, Chronic Pain Management, Parkinson's Disease, Epilepsy, Stroke Rehabilitation, Cognitive Enhancement & ADHD, Others (Anxiety, Insomnia, Alzheimer's)), By End User (Hospitals, Specialty Neuro-psychiatric Clinics, Out-patient Rehabilitation Centers, Home-care Settings, Academic & Research Institutes), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2019 - 2030
Market Size (2025)	USD 0.74 Billion
CAGR (2026-2031)	6.42%
Fastest Growing Segment	Asia Pacific
Largest Market	North America
Market Size (2031)	USD 1.07 Billion

Market Overview

The Global Non-invasive Brain Stimulation System Market is expected to grow from USD 0.74 Billion in 2025 to USD 1.07 Billion by 2031 at a 6.42% CAGR. Non-invasive brain stimulation systems comprise technologies engineered to modulate neural activity without surgical intervention, primarily through methods such as transcranial magnetic stimulation and transcranial direct current stimulation, for both therapeutic and investigative applications. The market's expansion is significantly driven by the escalating global prevalence of neurological and psychiatric disorders, including depression and Parkinson's disease, alongside a growing preference for non-pharmacological treatment modalities and continuous advancements in device technology facilitating enhanced efficacy and user accessibility.

However, a significant challenge impeding market growth remains the limited conclusive evidence regarding the long-term efficacy and safety of these systems across a broad spectrum of conditions, which directly impacts widespread clinical adoption and adequate reimbursement policies. Despite extensive efforts, providing recent statistical numerical data from industrial associations for the Global Non-invasive Brain Stimulation System Market is challenging due to the specific and restrictive sourcing requirements.

Key Market Drivers

Rising burden of neurological and psychiatric disorders
The rising prevalence of neurological and psychiatric disorders significantly fuels the expansion of the global non-invasive brain stimulation system market. As an increasing number of individuals worldwide contend with conditions such as depression, Alzheimer's disease, and Parkinson's disease, the demand for effective and accessible treatment modalities intensifies. Non-invasive brain stimulation therapies offer a compelling alternative to traditional pharmacological or invasive surgical interventions, often associated with systemic side effects or significant risks. According to a news article in October 2025, reporting on the World Health Organization's new Global status report on neurology, neurological conditions now affect more than 40% of the global population, exceeding 3 billion people, underscoring the vast patient pool requiring innovative care solutions. This substantial burden drives continuous research and development into non-invasive brain stimulation techniques to address unmet medical needs and improve patient quality of life.

Technological innovations drive adoption and home-based care
Technological advancements in device development further propel the market forward by enhancing the efficacy, safety, and user-friendliness of non-invasive brain stimulation systems. Innovations focus on improving targeting precision, increasing portability, and integrating smart functionalities, such as real-time brain mapping and personalized treatment protocols. These developments contribute to broader clinical adoption and enable a shift towards home-care settings, making therapies more accessible. For instance, according to New Market Pitch, in October 2026, Flow Neuroscience, a company focusing on home-based brain stimulation, reported that more than 55,000 patients have been treated across its markets with its FDA-approved headset. Such widespread adoption signifies the impact of these technological strides, fostering the creation of next-generation devices with superior performance. Reflecting the growth within this specialized segment, according to New Market Pitch, in 2026, BrainsWay, a prominent company in non-invasive advanced therapy for brain illnesses, reported $52.2 million in revenue, highlighting the commercial viability of these innovations.

Download Free Sample Report

Key Market Challenges

Limited Long-Term Evidence Impedes Adoption
A significant challenge impeding the growth of the Global Non-invasive Brain Stimulation System Market is the limited conclusive evidence regarding the long-term efficacy and safety of these systems across a broad spectrum of conditions. This directly impacts widespread clinical adoption. Healthcare providers and institutions often require well-substantiated outcomes and robust safety profiles before integrating novel technologies into standard practice. The dearth of comprehensive, long-term evidence for diverse neurological and psychiatric conditions creates hesitancy among clinicians, limiting the rate at which these systems are adopted into routine patient care settings.

Payer Reimbursement Barriers Due to Data Gaps
This constraint also poses substantial hurdles for securing adequate reimbursement policies from payers and insurance providers. Without strong, conclusive data demonstrating sustained effectiveness and safety over time, payers are reluctant to offer comprehensive coverage, citing a lack of clear justification for the costs involved. This absence of consistent and favorable reimbursement creates significant financial barriers for patients seeking these therapies and for clinics looking to invest in the technology, thereby directly impeding the overall expansion and market penetration of non-invasive brain stimulation systems.

Key Market Trends

Broadening applications drive investment and adoption
The market for non-invasive brain stimulation systems is significantly influenced by the broadening array of therapeutic and cognitive enhancement applications beyond traditional indications. This trend involves expanding the use of these technologies to address a wider spectrum of neurological and psychiatric conditions, and for improving cognitive functions. This expansion drives increased investment in clinical research and product development, attracting new patient populations. For instance, according to MindMaze Therapeutics, in October 2026, a multi-site program demonstrated a threefold increase in motor-training dose using their home-based MindMotion rehabilitation platform for neurorehabilitation patients. This highlights growing acceptance and application in diverse therapeutic areas.

Diversification of stimulation modalities and rising funding
Another crucial trend shaping the global non-invasive brain stimulation system market is the diversification of stimulation modalities beyond established transcranial magnetic stimulation and transcranial direct current stimulation. This involves the emergence and increasing research into novel techniques such as transcranial focused ultrasound and optical stimulation, each offering unique advantages in terms of penetration depth and focality. This diversification caters to unmet clinical needs and expands potential applications, creating new market segments. As reported by the Focused Ultrasound Foundation in August 2026, funding for focused ultrasound research increased by approximately $10 million in 2025. This highlights concerted efforts toward exploring and commercializing new forms of stimulation.

Segmental Insights

Growth drivers for the Asia Pacific non-invasive brain stimulation market
The Asia Pacific segment is experiencing significant growth in the Global Non-invasive Brain Stimulation System Market, driven by the increasing prevalence of neurological and psychiatric disorders alongside a rising acceptance of non-invasive treatment modalities. Expanding healthcare expenditure and continuous improvements in infrastructure across the region, particularly in emerging economies like China and India, are crucial factors. Furthermore, governmental initiatives, such as India's National Health Mission, actively promote the adoption of advanced medical technologies in public hospitals, thereby fostering demand for non-invasive brain stimulation systems and positioning Asia Pacific as a rapidly expanding market.

Regional Insights

Drivers of North America's leadership in non-invasive brain stimulation
North America dominates the global non-invasive brain stimulation system market, driven by a convergence of critical factors. The region possesses a robust healthcare infrastructure and experiences a high prevalence of neurological and psychiatric disorders, which collectively stimulate demand for advanced therapeutic solutions. Furthermore, extensive clinical research and development endeavors foster continuous innovation and facilitate the early adoption of new technologies. This leadership is significantly reinforced by favorable reimbursement policies and a proactive regulatory environment, exemplified by the U.S. Food and Drug Administration's (FDA) approvals for various non-invasive brain stimulation devices, enhancing market accessibility and growth.

Recent Developments

• In December 2025, Flow Neuroscience received FDA approval for its FL-100 at-home brain stimulation device for the treatment of moderate to severe major depressive disorder. This marked a significant milestone, allowing clinicians in the United States to prescribe a novel non-drug therapy as both a standalone and adjunctive treatment. The device, worn as a headset, delivers transcranial direct current stimulation to a brain region associated with mood. This approval underscores the growing acceptance and availability of accessible, at-home non-invasive brain stimulation solutions for mental health conditions.
• In October 2025, Ampa announced the nationwide rollout of its FDA-cleared Ampa One system, a portable non-invasive brain stimulation device. This expansion followed an oversubscribed $8.5 million funding round, signifying a substantial step in making advanced brain stimulation more accessible to patients across the United States. The company emphasizes the device's practical, portable, and affordable nature, which is intended to increase patient access to this technology. Additionally, Ampa is developing a groundbreaking Ampa One Day protocol, aiming to condense multi-week transcranial magnetic stimulation treatments into a single day.
• In March 2025, the U.S. Food and Drug Administration granted Breakthrough Device designation to a non-invasive brain stimulation device, the XCSITE platform, developed by Pulvinar Neuro and acquired by Electromedical Products International, Inc. This innovative platform, which emits very weak electrical currents to the brain, targets altering brain waves implicated in major depressive disorder. This designation accelerates the development and review process for the device, bringing it closer to market availability for patients suffering from this condition. Clinical trials had previously demonstrated the device's efficacy in significantly reducing symptom severity.
• In October 2024, Cognito Therapeutics, based in Cambridge, Massachusetts, advanced its Spectris system, a non-invasive neuromodulation device. This system is designed to deliver proprietary gamma frequency light and sound stimulation, aiming to evoke specific brain oscillations to treat central nervous system diseases. The company reported continued statistically significant separation of activities of daily living over a 12-month period. This technology represents a focused effort in developing disease-modifying therapies for conditions such as Alzheimer's disease, thereby expanding the applications within the global non-invasive brain stimulation market.

Key Market Players

• Medtronic plc
• Boston Scientific Corporation
• BrainsWay Ltd
• Neuronetics Inc.
• Magstim Group Ltd
• Highland Instruments
• Soterix Medical Inc
• Flow Neuroscience AB
• NeoSync Inc
• Halo Neuroscience

By Technology	By Application	By End User	By Region
Transcranial Magnetic Stimulation (TMS) Transcranial Electrical Stimulation (tES)	Major Depressive Disorder Chronic Pain Management Parkinson's Disease Epilepsy Stroke Rehabilitation Cognitive Enhancement & ADHD Others (Anxiety, Insomnia, Alzheimer's)	Hospitals Specialty Neuro-psychiatric Clinics Out-patient Rehabilitation Centers Home-care Settings Academic & Research Institutes	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Non-invasive Brain Stimulation System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-invasive Brain Stimulation System Market, By Technology:

• Transcranial Magnetic Stimulation (TMS)
• Transcranial Electrical Stimulation (tES)

• Non-invasive Brain Stimulation System Market, By Application:

• Major Depressive Disorder
• Chronic Pain Management
• Parkinson's Disease
• Epilepsy
• Stroke Rehabilitation
• Cognitive Enhancement & ADHD
• Others (Anxiety, Insomnia, Alzheimer's)

• Non-invasive Brain Stimulation System Market, By End User:

• Hospitals
• Specialty Neuro-psychiatric Clinics
• Out-patient Rehabilitation Centers
• Home-care Settings
• Academic & Research Institutes

• Non-invasive Brain Stimulation System Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE